This study aims to determine whether advanced ROS1 gene-rearranged NSCLC (ROS1+ NSCLC) has a higher than expected thromboembolic event (TEE) rate.
The risk of peridiagnostic TEEs is significantly elevated in patients with advanced ROS+ NSCLC compared to EGFR+ and KRAS+ cases. TEE risk may be similarly elevated in ALK+ NSCLC. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2018.12.001
Authors: Terry L Ng, Derek E Smith, Rao Mushtaq, Tejas Patil, Anastasios Dimou, Shuo Yang, Qian Liu, Xuefei Li, Caicun Zhou, Robert T Jones, Megan M Tu, Flora Yan, I Alex Bowman, Stephen V Liu, Siera Newkirk, Joshua Bauml, Robert C Doebele, Dara L Aisner, Dexiang Gao, Shengxiang Ren, D Ross Camidge